Carbimazole, Thiamazole (Methimazole)

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8483
R27817
Yoshihara (Controls exposed to PTU), 2021 Cheiloschisis, palatoschisis 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 7.99 [0.32;201.71] C
excluded (control group)
0/23   1/541 1 23
ref
S8482
R27795
Yoshihara (Controls unexposed, sick), 2021 Cheiloschisis, palatoschisis 1st trimester retrospective cohort unexposed, sick Adjustment: No 7.01 [0.28;177.06] C 0/23   1/475 1 23
ref
S3364
R6132
Seo (control exposed to PTU), 2018 Cleft lip and cleft palate (Q35–Q37) 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.74 [0.10;5.69] C
excluded (control group)
1/1,120   12/9,930 13 1,120
ref
S3365
R6144
Seo (control unexposed, NOS), 2018 Cleft lip and cleft palate (Q35–Q37) 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.72 [0.10;5.10] 1/1,120   3,446/2,872,109 3,447 1,120
ref
Total 2 studies 1.54 [0.19;12.70] 3,448 1,143
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yoshihara (Controls unexposed, sick), 2021Yoshihara, 2021 1 7.01[0.28; 177.06]12334%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: unclearROB mesure: criticalROB reporting: moderate Seo (control unexposed, NOS), 2018Seo, 2018 2 0.72[0.10; 5.10]3,4471,12066%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 28% 1.54[0.19; 12.70]3,4481,1430.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: control unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.54[0.19; 12.70]3,4481,14328%NAYoshihara (Controls unexposed, sick), 2021 Seo (control unexposed, NOS), 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.72[0.10; 5.14]3,4471,120 -NASeo (control unexposed, NOS), 2018 1 unexposed, sickunexposed, sick 7.01[0.28; 177.06]123 -NAYoshihara (Controls unexposed, sick), 2021 1 Tags Adjustment   - No  - No 7.01[0.28; 177.06]123 -NAYoshihara (Controls unexposed, sick), 2021 1   - Yes  - Yes 0.72[0.10; 5.14]3,4471,120 -NASeo (control unexposed, NOS), 2018 1 All studiesAll studies 1.54[0.19; 12.70]3,4481,14328%NAYoshihara (Controls unexposed, sick), 2021 Seo (control unexposed, NOS), 2018 20.220.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3364, 8483

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.72[0.10; 5.14]3,4471,120 -NASeo (control unexposed, NOS), 2018 1 unexposed, sick controlsunexposed, sick controls 7.01[0.28; 177.06]123 -NAYoshihara (Controls unexposed, sick), 2021 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.73[0.18; 16.14]141,14333%NAYoshihara (Controls exposed to PTU), 2021 Seo (control exposed to PTU), 2018 20.510.01.0